The use of dapagliflozin in the treatment of type 1 diabetes in a 36-year-old patient
, 1
Abstract
Until recently, insulin was the only medicine used in therapy of type 1 diabetes mellitus (T1DM).As our knowledge of pathomechanisms involved in diabetes evolves, other promising drugs are being introduced, e.g. metformin in the patients with insulin resistance or sodium-glucose cotransporter 2 (SGLT-2) inhibitors in patients with poor metabolic control. The first SGLT-2 inhibitor (dapagliflozin) has been recently approved by the National Institute for Health and Clinical Excellence (NICE) for additional treating of poorly controlled type 1 diabetes. This article presents a case of patient with type 1 diabetes successfully treated with insulin and dapagliflozin at a daily dose of 5 mg.
Keywords: diabetes mellitus type 1dapagliflozincontinuous glucose monitoring
References
- Araszkiewicz A, Bandurska-Stankiewicz E, Budzyński A, et al. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology. 2019; 8(1): 1–95.
- Livingstone R, Boyle JG, Petrie JR. A new perspective on metformin therapy in type 1 diabetes. Diabetologia. 2017; 60(9): 1594–1600.
- Petrie JR, Chaturvedi N, Ford I, et al. Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017; 5(8): 597–609.
- Danne T, Garg S, Peters AL, et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors. Diabetes Care. 2019; 42(6): 1147–1154.
- Sugiyama S, Jinnouchi H, Kurinami N, et al. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb. 2018; 25(6): 467–476.
- Maj-Podsiadło A, Cichocka E, Gumprecht J. SGLT-2 inhibitors as adjunctive to insulin therapy in type 1 diabetes. Clinical Diabetology. 2020; 9(3): 189–192.
- Paik J, Blair HA, Paik J, et al. Dapagliflozin: a review in type 1 diabetes. Drugs. 2019; 79(17): 1877–1884.
- Dandona P, Mathieu C, Phillip M, et al. DEPICT-1 Investigators. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: the DEPICT-1 52-week study. Diabetes Care. 2018; 41(12): 2552–2559.
- Trojanowska-Grigoriew M, Majkowska L. Diabetic ketoacidosis without hyperglycemia as a complication of SGLT2 inhibitors treatment. Clinical Diabetology. 2016; 5(2): 66–72.
- Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015; 373(22): 2117–2128.
- Sarraju A, Li J, Cannon CP, et al. Erratum. The relative and combined ability of high-sensitivity cardiac troponin t and n-terminal pro-b-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes care 2014;37:295-303. Diabetes Care. 2015; 38(7): 1393–1897.
- Berg DD, Wiviott SD, Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369(14): 1317–1326.
- Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. Diabetes Care. 2019; 42(8): 1593–1603.
- Araszkiewicz A, Bandurska-Stankiewicz E, Budzyński A, et al. 2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clinical Diabetology. 2019; 8(1): 1–95.